COURAGE Trial: Vibegron for BPH Patients with Persistent OAB Symptoms - David Staskin
David Staskin
David Staskin discusses the COURAGE trial, a phase three study evaluating the efficacy of Vibegron, a beta-3 adrenergic receptor agonist, in men with BPH and persistent OAB symptoms despite alpha-blocker treatment.